Liminal BioSciences

Liminal BioSciences, Inc. operates as a clinical stage biopharmaceutical company. The firm focuses on developing distinctive novel small molecule therapeutics for inflammatory, fibrotic, and metabolic diseases using drug discovery platform and a data driven approach. The firm has business operations in Canada and the United Kingdom. Its small molecule product candidate, fezagepras, has completed a Phase 1 multi-ascending dose clinical trial and anticipate conducting a comparative Phase 1a single ascending dose clinical trial to provide comparative data to support development plan. The company was founded on October 14, 1994 and is headquartered in Laval, Canada.

Earnings data Q2 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Liminal BioSciences is a biopharmaceutical corporation supplying state-of-the-art technologies for bio-separations as well as therapeutic products. It specializes in discovering, developing, and commercializing novel small molecule compounds for respiratory, liver, and renal diseases. The company focuses specifically on developing solutions for rare and orphan diseases. Liminal BioSciences was founded in 1992 and is headquartered in Laval, Quebec.

$40.8M of cash and cash equivalents at September 30, 2022 Discontinuation of fezagepras development Termination of legacy CDMO agreement for cash savings of $33.1 million Net loss from continuing operations of $4.5 million during the quarter ended September 30, 2022 compared to $9.7 million net loss for the same period 2021 Current cash runway is anticipated to support our near-term development goals into the fourth quarter of fiscal 2023 Possibilities to sell non-core assets to further extend runway into 2024 Changes to strengthen executive leadership team LAVAL, QC and CAMBRIDGE, England , Nov. 9, 2022 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ: LMNL) ("Liminal BioSciences" or the "Company"), today reported its financial results for the third quarter ended September 30, 2022. "We are pleased to be entering the fourth quarter of 2022 with anticipated cash and cash equivalents to fund our near-term development goals into the fourth quarter of 2023, with possibilities to further extend that runway into 2024 with the sale of non-core, real estate assets," stated Bruce Pritchard, Chief Executive Officer of Liminal BioSciences.

Liminal BioSciences Reports Third Quarter 2022 Financial Results and Business Highlights

LAVAL, QC and CAMBRIDGE, England , Nov. 8, 2022 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), today announced that it plans to report its third quarter 2022 financial results after market close on November 9, 2022. Liminal will host a conference call and webcast to discuss financial results at 8:30 am (ET) on Thursday November 10, 2022.

Liminal BioSciences to Report Third Quarter 2022 Financial Results on November 9, 2022

LAVAL, QC and CAMBRIDGE, England , Sept. 1, 2022 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company") announced today that it received confirmation from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq") that the Company's application to transfer its common shares from The Nasdaq Global Market to The Nasdaq Capital Market, as allowed under Listing Rule 5810(c)(3)(A), had been approved.

Liminal BioSciences Announces Listing Transfer to Nasdaq Capital Market

LAVAL, QC and CAMBRIDGE, England , Aug. 29, 2022 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), a development-stage biopharmaceutical company, announced that Bruce Pritchard, Chief Executive Officer at Liminal BioSciences is scheduled to present a company overview on Wednesday 14th September at 09:30am (ET) during the H.C. Wainwright 24th Annual Global Investment Conference taking place at The Lotte New York Palace on 12-14th September 2022.

Liminal Biosciences to Present at H.C. Wainwright 24th Annual Global Investment Conference

Termination results in anticipated cash savings of $33.1 million Removes last of legacy contracts associated with former plasma-derived therapeutics business LAVAL, QC and CAMBRIDGE, ENGLAND , Aug. 25, 2022 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), a development-stage biopharmaceutical company, announced today that, effective immediately, its long-term legacy Master Services Agreement, entered into in May 2015 as amended, relating to its previously owned plasma-derived therapeutics business ("CDMO Agreement"), was terminated by mutual agreement between the parties. The Company had previously sent an early five-year termination notice to terminate the CDMO Agreement in August 2021.

Liminal BioSciences Announces Termination of Legacy CDMO Contract

$55.8M of cash and cash equivalents at June 30, 2022 Discontinuation of fezagepras development Net loss from continuing operations of $6.5 million during the quarter ended June 30, 2022 compared to $12.6 million during the quarter ended June 30, 2021 LAVAL, QC and CAMBRIDGE, England , Aug. 9, 2022 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), today reported its financial results for the second quarter ended June 30, 2022. Liminal BioSciences will host a conference call and webcast to discuss financial results at 8:30 am (ET) on Wednesday August 10, 2022.

Liminal BioSciences Reports Second Quarter 2022 Financial Results and Business Highlights

Based on results from an early-stage study, Liminal BioSciences (LMNL) decides to discontinue the development of its lead pipeline candidate, fezagepras.

Liminal (LMNL) Ends Development of Lead Candidate, Stock Down

LAVAL, QC and CAMBRIDGE, England , July 21, 2022 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company") today announced that it has discontinued development of fezagepras. The decision to discontinue the development of fezagepras is based on results from the Phase 1a single ascending dose ("SAD") clinical trial, which indicated that fezagepras was significantly inferior compared to Sodium Phenylbutyrate as a nitrogen scavenger.

Liminal BioSciences Announces Discontinuation of Fezagepras Development

LAVAL, QC and CAMBRIDGE, England , June 6, 2022 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company") announced the voting results from its Annual General Meeting of Shareholders ("AGM") held virtually on June 6, 2022. A total of 20,209,035 common shares were voted, representing 65.10% of the votes attached to the issued and outstanding common shares of Liminal BioSciences.

Liminal BioSciences Announces Voting Results of its 2022 Annual General Meeting of Shareholders

LAVAL, QC and CAMBRIDGE, England , May 23, 2022 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ: LMNL) ("Liminal BioSciences" or the "Company"), today announced that the first subject has been dosed in the Company's Phase 1a single ascending dose ("SAD") randomized, open label, cross over clinical trial of fezagepras to evaluate the safety, tolerability, and pharmacokinetics of single ascending dose of fezagepras compared to Sodium Phenylbutyrate in healthy volunteers. "This Phase 1a SAD clinical trial is designed as a head-to-head comparison with Sodium Phenylbutyrate to provide us with further data to determine if fezagepras is worth developing for one of the many potential indications where nitrogen scavenging is beneficial," stated Bruce Pritchard, Chief Executive Officer of Liminal BioSciences.

Liminal BioSciences Announces First Subject Dosed in Phase 1a Single Ascending Dose Clinical Trial of Fezagepras

Liminal BioSciences Inc. (NASDAQ:LMNL ) Q1 2022 Earnings Conference Call May 11, 2022 8:30 AM ET Company Participants Shrinal Inamdar - Investor Relations & Communications Manager Bruce Pritchard - Chief Executive Officer Nicole Rusaw - Interim Chief Financial Officer Conference Call Participants Ed Arce - H.C. Wainwright Operator Good day and welcome to the Liminal BioSciences, Inc. First Quarter 2022 Results Conference Call.

Liminal BioSciences Inc. (LMNL) CEO Bruce Pritchard on Q1 2022 Results - Earnings Call Transcript

Liminal BioSciences Inc. (LMNL) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Liminal BioSciences Inc. (LMNL) Could Find Support Soon, Here's Why You Should Buy the Stock Now

Planned Phase 1a Single Ascending Dose ("SAD") clinical trial of fezagepras expected to commence in Q2 2022 Completion of analysis of safety and pharmacokinetic ("PK") data from Phase 1 Multiple Ascending Dose ("MAD") clinical trial of fezagepras Repayment in full of the $39.1M secured loans and release of security on the Company's assets Net loss of $11.2 million during the quarter ended March 31, 2022 compared to $20.8 million during the quarter ended March 31, 2021 LAVAL, QC and CAMBRIDGE, England , May 10, 2022 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ: LMNL) ("Liminal BioSciences" or the "Company"), today reported its financial results for the first quarter ended March 31, 2022. "We have already made significant progress in the first quarter of 2022 having eliminated the Company's debt and refined our data-driven development plan for our pipeline," stated Bruce Pritchard, Chief Executive Officer of Liminal BioSciences.

Liminal BioSciences Reports First Quarter 2022 Financial Results and Business Highlights

LAVAL, QC and CAMBRIDGE, ENGLAND , May 9, 2022 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ: LMNL) ("Liminal BioSciences" or the "Company"), today announced that it plans to report its first quarter 2022 financial results after market close on May 10, 2021. Liminal will host a conference call and webcast to discuss financial results at 8:30 am (ET) on Wednesday May 11, 2022.

Liminal BioSciences to Report First Quarter 2022 Financial Results on May 10, 2022

LAVAL, QC, and CAMBRIDGE, England , May 9, 2022 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company, announced that Bruce Pritchard, Chief Executive Officer at Liminal BioSciences is scheduled to present a company overview at the following upcoming investor conferences: H.C. Wainwright Global Investment Conference on Tuesday 24th May at 2:30-3:00 PM (EDT).

Liminal Biosciences to Present at Upcoming Investor Conferences

Planned Phase 1a Single Ascending Dose ("SAD") clinical trial, commencing in Q2 2022, to compare fezagepras with sodiumphenylbutyrate as a nitrogen scavenger Repayment in full of the $39.1M secured loan and release of security on the Company's assets Completion of the Phase 1 Multi-Ascending Dose ("MAD") clinical trial of fezagepras Closing of the sale of the plasma-derived therapeutics business and sale of a Rare Pediatric Disease Priority Review Voucher LAVAL, QC, and CAMBRIDGE, England , March 17, 2022 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), today reported its financial results for the fourth quarter and year ended December 31, 2021. "The leadership team and I are pleased to have successfully delivered on our objective of simplifying our business structure over the past 12 months as part of our evolution in becoming a streamlined small molecules business," stated Bruce Pritchard, Chief Executive Officer of Liminal BioSciences.

Liminal BioSciences Reports Fourth Quarter and Year End 2021 Financial Results

Analysis of PK data from Phase 1 Multi-Ascending Dose ("MAD") clinical trial completed Data observed shows that fezagepras has nitrogen scavenging properties Planned Phase 1a Single Ascending Dose ("SAD") trial, commencing in Q2 2022, to compare fezagepras with sodium phenylbutyrate as a nitrogen scavenger LAVAL, QC and CAMBRIDGE, England , March 14, 2022 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), today provides an update on plans for the further development of its lead compound fezagepras. This announcement follows the completion of the Company's analysis of the pharmacokinetic ("PK") data from its Phase 1 MAD study of fezagepras in healthy volunteers.

Liminal BioSciences Provides Update on Its Lead Drug Candidate Fezagepras

LAVAL, QC, and CAMBRIDGE, ENGLAND , March 7, 2022 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ: LMNL) ("Liminal BioSciences" or the "Company"), announced today that on March 4, 2022, it received a written notice (the "Notice") from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq") indicating that the Company is not in compliance with the minimum bid price requirement of US$1.00 per share under the Nasdaq Listing Rules (the "Listing Rules"). Based on the closing bid price of the Company's listed securities for the last 30 consecutive business days from January 20, 2022 to March 3, 2022, the Company has failed to meet the minimum bid price requirement set forth in Listing Rule 5550(a)(2) during that period.

Liminal BioSciences Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement

Repayment eliminates total debt of $39.1M Early Repayment results in: Total interest savings of CA$9.1M Immediate termination of Loan Agreement and release of security interests over all of its secured assets, including Intellectual Property Immediate termination of Royalty Stream Agreement entered with Structured Alpha LP Immediate cancellation of all Warrants issued pursuant to the Restructuring Agreement Immediate release from all covenants under the Loan and Warrant Agreements LAVAL, QC and CAMBRIDGE, England, Feb. 16, 2022 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), announced today that it has repaid its debt of $39.1 million to Structured Alpha LP ("SALP") in full, using cash on hand. The loan repayment terminates the Company's creditor relationship with SALP.

Liminal BioSciences Repays its Secured Debt Ending its Creditor Relationship with Structured Alpha LP

Following the analysis of the preliminary pharmacokinetic data from the Phase I MAD trial, Liminal BioSciences Inc (NASDAQ: LMNL) said that it would not be progressing the development of fezagepras for idiopathic pulmonary fibrosis (IPF) nor hypertriglyceridemia.  The Company has completed the Phase 1 MAD trial and continues to analyze the resulting data.

Liminal BioSciences Pauses Development Of Fezagepras, Outlines R&D Priorities For 2022

LAVAL, QC and CAMBRIDGE, England, Jan. 19, 2022 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), today provided an update in which it outlined key corporate and research and development priorities for 2022. "2021 was an instrumental year in simplifying our business strategy and providing a cash runway that positions us to focus our resources on our small molecules business," stated Bruce Pritchard, Chief Executive Officer of Liminal BioSciences.

Liminal BioSciences Announces Strategic Priorities For 2022

Closing of the Sale of a Rare Pediatric Disease Priority Review Vou cher for gross proceeds of USD105M Closing of the Sale of the Remaining Plasma-Derived Therapeutics Business to Kedrion S.p.A Completion of the Clinical Phase of the Phase 1 Multi-Ascending Dose Clinical Trial in Fezagepras LAVAL, QC and CAMBRIDGE, England, Nov. 15, 2021 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), today reported its financial results for the third quarter ended September 30, 2021. "In addition to adding a significant sum of cash to our balance sheet this quarter, we have also removed significant costs from our operations due to the divestment of our remaining plasma-derived therapeutics business," stated Bruce Pritchard, Chief Executive Officer of Liminal BioSciences.

Liminal BioSciences Reports Third Quarter 2021 Financial Results

Liminal BioSciences Inc. (LMNL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Liminal BioSciences Inc. (LMNL) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

LAVAL, QC and CAMBRIDGE, England, Oct. 15, 2021 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), announced today that it has closed on the sale of the remainder of the Company's plasma-derived therapeutics business (the "Second Closing") under the terms of the previously-announced Share Purchase Agreement entered into by the Company and Kedrion S.p.A. ("Kedrion").

Liminal BioSciences Announces Closing of Sale of Remaining Plasma-Derived Therapeutics Business

LAVAL, QC and CAMBRIDGE, England, Sept. 28, 2021 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ: LMNL) ("Liminal BioSciences" or the "Company"), announced today that its subsidiary Prometic Biotherapeutics Inc. ("PBT") has closed on the sale of its Priority Review Voucher ("PRV") for USD 105 million.

News for Liminal BioSciences Stock (LMNL)